X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse STRIDES PHARMA SCIENCE with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs MYLAN (US) - Comparison Results

STRIDES PHARMA SCIENCE    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 STRIDES PHARMA SCIENCE   MYLAN
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
MYLAN
Dec-14
STRIDES PHARMA SCIENCE/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,1474,254-   
Low Rs6422,998-   
Sales per share (Unadj.) Rs317.21,456.2-  
Earnings per share (Unadj.) Rs7.8175.4-  
Cash flow per share (Unadj.) Rs25.1282.4-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.3723.9-  
Shares outstanding (eoy) m89.50378.37-   
Bonus/Rights/Conversions ESOPOI-  
Price / Sales ratio x2.82.5 113.2%   
Avg P/E ratio x114.020.7 551.7%  
P/CF ratio (eoy) x35.712.8 278.0%  
Price / Book Value ratio x3.35.0 65.1%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,0581,371,817 5.8%   
No. of employees `0002.525.0 10.0%   
Total wages/salary Rs m4,3410-   
Avg. sales/employee Rs Th11,325.822,039.1 51.4%   
Avg. wages/employee Rs Th1,731.40-   
Avg. net profit/employee Rs Th280.12,655.0 10.5%   
INCOME DATA
Net Sales Rs m28,394550,976 5.2%  
Other income Rs m941-3,212 -29.3%   
Total revenues Rs m29,334547,765 5.4%   
Gross profit Rs m3,965137,030 2.9%  
Depreciation Rs m1,54040,467 3.8%   
Interest Rs m1,96223,766 8.3%   
Profit before tax Rs m1,40369,586 2.0%   
Minority Interest Rs m0-285 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m972,926 3.3%   
Profit after tax Rs m70266,374 1.1%  
Gross profit margin %14.024.9 56.2%  
Effective tax rate %6.94.2 164.9%   
Net profit margin %2.512.0 20.5%  
BALANCE SHEET DATA
Current assets Rs m24,836484,381 5.1%   
Current liabilities Rs m18,993378,689 5.0%   
Net working cap to sales %20.619.2 107.3%  
Current ratio x1.31.3 102.2%  
Inventory Days Days7178 90.9%  
Debtors Days Days113107 105.7%  
Net fixed assets Rs m34,289127,467 26.9%   
Share capital Rs m89519,484 4.6%   
"Free" reserves Rs m23,6510-   
Net worth Rs m24,546273,890 9.0%   
Long term debt Rs m15,513409,164 3.8%   
Total assets Rs m65,4371,103,202 5.9%  
Interest coverage x1.73.9 43.7%   
Debt to equity ratio x0.61.5 42.3%  
Sales to assets ratio x0.40.5 86.9%   
Return on assets %4.18.2 49.8%  
Return on equity %2.924.2 11.8%  
Return on capital %6.913.6 50.6%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m14,9620-   
CASH FLOW
From Operations Rs m1,87172,426 2.6%  
From Investments Rs m5,826-57,117 -10.2%  
From Financial Activity Rs m-10,157-19,084 53.2%  
Net Cashflow Rs m-2,615-3,775 69.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.37 Rs / USD

Compare STRIDES PHARMA SCIENCE With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare STRIDES PHARMA SCIENCE With: PIRAMAL ENTERPRISES  GLENMARK PHARMA  CIPLA  JUBILANT LIFE SCIENCES  PLETHICO PHARMA  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES SHASUN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Oct 1, 2018 | Updated on Oct 1, 2018

Here's an analysis of the annual report of STRIDES SHASUN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES SHASUN LTD. Also includes updates on the valuation of STRIDES SHASUN LTD.

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Nov 20, 2018 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - AUROBINDO PHARMA COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS